CN119072312A - 用于改善运动表现的方法和组合物 - Google Patents

用于改善运动表现的方法和组合物 Download PDF

Info

Publication number
CN119072312A
CN119072312A CN202280092060.3A CN202280092060A CN119072312A CN 119072312 A CN119072312 A CN 119072312A CN 202280092060 A CN202280092060 A CN 202280092060A CN 119072312 A CN119072312 A CN 119072312A
Authority
CN
China
Prior art keywords
fontan
udenafil
patients
patient
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280092060.3A
Other languages
English (en)
Chinese (zh)
Inventor
J·L·耶格尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mezzion Pharma Co Ltd
Original Assignee
Mezzion Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mezzion Pharma Co Ltd filed Critical Mezzion Pharma Co Ltd
Publication of CN119072312A publication Critical patent/CN119072312A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN202280092060.3A 2021-12-20 2022-12-20 用于改善运动表现的方法和组合物 Pending CN119072312A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163291858P 2021-12-20 2021-12-20
US63/291,858 2021-12-20
PCT/US2022/000033 WO2023121689A1 (en) 2021-12-20 2022-12-20 Methods and compositions for improving exercise performance

Publications (1)

Publication Number Publication Date
CN119072312A true CN119072312A (zh) 2024-12-03

Family

ID=85382567

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280092060.3A Pending CN119072312A (zh) 2021-12-20 2022-12-20 用于改善运动表现的方法和组合物

Country Status (8)

Country Link
US (1) US20240285630A1 (https=)
EP (1) EP4452273A1 (https=)
JP (1) JP2025504706A (https=)
CN (1) CN119072312A (https=)
AU (1) AU2022419178A1 (https=)
CA (1) CA3243958A1 (https=)
MX (1) MX2024007796A (https=)
WO (1) WO2023121689A1 (https=)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TN2017000029A1 (en) 2014-08-12 2018-07-04 Mezzion Pharma Co Ltd Methods of improving myocardial performance in fontan patients using udenafil compositions
AU2020356193A1 (en) * 2019-09-24 2022-05-19 Children's Hospital Of Philadelphia Methods of improving exercise performance, single ventricular performance, and myocardial performance index (MPI) in single ventricle heart disease, using udenafil compositions

Also Published As

Publication number Publication date
MX2024007796A (es) 2025-04-02
CA3243958A1 (en) 2023-06-29
EP4452273A1 (en) 2024-10-30
US20240285630A1 (en) 2024-08-29
JP2025504706A (ja) 2025-02-17
AU2022419178A1 (en) 2024-08-08
WO2023121689A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
Guazzi et al. Long-term use of sildenafil in the therapeutic management of heart failure
US20250186448A1 (en) Formulations of udenafil
JP2024020187A (ja) ウデナフィル組成物を用いてフォンタン患者における心筋性能を改善する方法
JP2025118624A (ja) ウデナフィル組成物を用いた単心室心疾患における運動能力、単心室性能、および心筋性能指数（ｍｐｉ）を改善する方法
CN119072312A (zh) 用于改善运动表现的方法和组合物
Goldberg et al. Results of the Fontan Udenafil exercise longitudinal (FUEL) trial
Majchrowicz et al. Artificial Intelligence in Cardiology Examination: A Comparative Study of Physicians, ChatGPT-4, and ChatGPT-5
CN117672545A (zh) 一种验证肺动脉高压靶向药物的有效性的方法
Posters The Pulse of Asia 2017 Taipei
Posters The Pulse of Asia 2017 Taipei
HK1236115A1 (en) Methods of improving myocardial performance in fontan patients using udenafil compositions
HK1236115A (en) Methods of improving myocardial performance in fontan patients using udenafil compositions

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination